Rheacell Gmbh & Co. Kg

Rheacell Gmbh & Co. Kg company information, Employees & Contact Information

With late-stage data available for CVU and an ongoing pivotal phase 3 trial for RDEB, RHEACELL is a leading biopharmaceutical company that is dedicated to developing innovative therapies for patients suffering from severe inflammation driven diseases, such as RDEB and therapy resistant non-healing chronic venous ulcers based on our proprietary ABCB5+mesenchymal stromal cells (MSCs) platform technology - exclusively licensed by RHEACELL from Children´s Medical Center (CMCC), Harvard Medical School. Our mission is to provide a new and innovative standard of care for patients who currently have no satisfactory treatment options. We believe that our therapy can make a real difference for the lives of these patients. Our innovative proprietary cell therapy with ABCB5+ MSCs for the treatment of non-healing chronic venous wounds has already been granted with a national market approval for external/topical use in CVU patients, by the Paul-Ehrlich-Institute in Germany in 2021 (AMESANAR®). The cell therapy targets inflammation and is enabling recovery of normal physiological function and initiating neo-vascularization after topical application. With late-stage data available, our CVU phase-2b clinical trial across Germany is ongoing. With RDEB -orphan & rare-, "the worst disease you have never heard of", we are in a pivotal phase 3 clinical trials in Europe and the US with EBESANAR®. With our unique product characteristics, mode of action and the systemic (intra-venous) approach, our cells are first in class and best in class by targeting external and internal wounds, leading to a reduction of overall disease burden in patients by significant reduction of wounds, enabling recovery of normal physiological function of the affected tissue and preventing the formation of new wounds. We are specialists in clinical development and have full control over the entire workflow from bench to bedside, from pre-clinical development to a pivotal phase 3 trial and beyond.

Company Details

Employees
62
Founded
-
Address
Heidelberg, Im Neuenheimer Feld 517 69120, De
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Heidelberg, Im Neuenheimer Feld 517
Looking for a particular Rheacell Gmbh & Co. Kg employee's phone or email?

Rheacell Gmbh & Co. Kg Questions

News

RHEACELL and AOP Health enter into strategic partnership to commercialize novel somatic cell therapies in Europe - Yahoo Finance

RHEACELL and AOP Health enter into strategic partnership to commercialize novel somatic cell therapies in Europe Yahoo Finance

RHEACELL and AOP Health: Strategic Partnership to Deliver Breakthrough Therapies for the “Butterfly Children’s Disease” and Chronic Venous Wounds - Business Wire

RHEACELL and AOP Health: Strategic Partnership to Deliver Breakthrough Therapies for the “Butterfly Children’s Disease” and Chronic Venous Wounds Business Wire

Rheacell, AOP partner on stem cell therapy for epidermolysis bullosa - Epidermolysis Bullosa News

Rheacell, AOP partner on stem cell therapy for epidermolysis bullosa Epidermolysis Bullosa News

Cell Therapy Weekly: Digital Solution for Long-Term Follow-Up Studies - RegMedNet

Cell Therapy Weekly: Digital Solution for Long-Term Follow-Up Studies RegMedNet

Healing begins with research: Promising development program on stem cells in rare diseases - Pharmaceutical Technology

Healing begins with research: Promising development program on stem cells in rare diseases Pharmaceutical Technology

International Day of Older Persons: AOP Health Shines a Light on the Silent Burden of Venous Leg Ulcers - StreetInsider

International Day of Older Persons: AOP Health Shines a Light on the Silent Burden of Venous Leg Ulcers StreetInsider

Acute On Chronic Liver Failure Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | RHEACELL, Versantis, Martin Pharma, Grifols Therapeutics - Barchart.com

Acute On Chronic Liver Failure Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | RHEACELL, Versantis, Martin Pharma, Grifols Therapeutics Barchart.com

Top Rheacell Gmbh & Co. Kg Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant